| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $988,943 ) |
| | 2025 | 2025 | EVOQ THERAPEUTICS, INC. | 1600 HURON PARKWAY | ANN ARBOR | MI | 48109-5001 | WASHTENAW | USA | R44TR005293 | Novel immunotherapy against MOG antibody disease | 000 | 3 | NIH | 6/18/2025 | $988,943 |
|
| Issue Date FY: 2024 ( Subtotal = $1,756,491 ) |
| | 2024 | 2024 | EVOQ THERAPEUTICS, INC. | 1600 HURON PARKWAY | ANN ARBOR | MI | 48109-5001 | WASHTENAW | USA | R44TR005293 | Novel immunotherapy against MOG antibody disease | 000 | 2 | NIH | 7/11/2024 | $1,000,000 |
| | 2024 | 2024 | EVOQ THERAPEUTICS, INC. | 1600 HURON PARKWAY | ANN ARBOR | MI | 48109-5001 | WASHTENAW | USA | R44DK135218 | New approach for immune modulation against T1D | 001 | 2 | NIH | 8/21/2024 | $756,491 |
| | 2024 | 2024 | EVOQ THERAPEUTICS, INC. | 1600 HURON PARKWAY | ANN ARBOR | MI | 48109-5001 | WASHTENAW | USA | R44DK135218 | New approach for immune modulation against T1D | 002 | 2 | NIH | 9/18/2024 | -$194,626 |
| | 2024 | 2024 | EVOQ THERAPEUTICS, INC. | 1600 HURON PARKWAY | ANN ARBOR | MI | 48109-5001 | WASHTENAW | USA | R44DK135218 | New approach for immune modulation against T1D | 002 | 2 | NIH | 9/18/2024 | $194,626 |
| | 2024 | 2023 | EVOQ THERAPEUTICS, INC. | 1600 HURON PARKWAY | ANN ARBOR | MI | 48109-5001 | WASHTENAW | USA | R44DK135218 | New approach for immune modulation against T1D | 000 | 1 | NIH | 11/28/2023 | $0 |
| | 2024 | 2023 | EVOQ THERAPEUTICS, INC. | 1600 HURON PARKWAY | ANN ARBOR | MI | 48109-5001 | WASHTENAW | USA | R44DK135218 | New approach for immune modulation against T1D | 000 | 1 | NIH | 11/28/2023 | $0 |
| | 2024 | 2022 | EVOQ THERAPEUTICS, INC. | 1600 HURON PARKWAY | ANN ARBOR | MI | 48109-5001 | WASHTENAW | USA | R43AI172705 | Novel immunotherapy against MOG antibody disease | 000 | 1 | NIH | 3/19/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $761,809 ) |
| | 2023 | 2023 | EVOQ THERAPEUTICS, INC. | 1600 HURON PARKWAY | ANN ARBOR | MI | 48109-5001 | WASHTENAW | USA | R44DK135218 | New approach for immune modulation against T1D | 000 | 1 | NIH | 9/19/2023 | $648,889 |
| | 2023 | 2023 | EVOQ THERAPEUTICS, INC. | 1600 HURON PARKWAY | ANN ARBOR | MI | 48109-5001 | WASHTENAW | USA | R44DK135218 | New approach for immune modulation against T1D | 000 | 1 | NIH | 9/19/2023 | $112,920 |
|
| Issue Date FY: 2022 ( Subtotal = $287,733 ) |
| | 2022 | 2022 | EVOQ THERAPEUTICS LLC | 534 GLENDALE CIR | ANN ARBOR | MI | 48103-4177 | WASHTENAW | USA | R43AI172705 | Novel immunotherapy against MOG antibody disease | 000 | 1 | NIH | 7/15/2022 | $287,733 |
|
|
